Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Summary

Patients with acute myeloid leukemia(AML) recurred after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis.The investigators developed donor-derived chimeric antigen receptor modified-T cell(CART) to target CD123 for the treatment of AML. The investigators start the Phase I study aimed to treat recurred post-transplantation AML patients using donor-derived CAR-T. The purpose of this study is to assess the safety and effectiveness of anti-CD123 CAR-T cells in patients.

Timeline

Start

2017-03-25

Primary completion

2019-03-18

Completion

2021-03-18

Drugs

Indications